Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P49916

UPID:
DNLI3_HUMAN

ALTERNATIVE NAMES:
DNA ligase III; Polydeoxyribonucleotide synthase [ATP] 3

ALTERNATIVE UPACC:
P49916; E5KLB5; E5KLB6; Q16714; Q6NVK3

BACKGROUND:
DNA ligase 3, with its alternative names DNA ligase III and Polydeoxyribonucleotide synthase [ATP] 3, is integral to cellular DNA repair processes. It operates in two distinct forms: Isoform 3, which partners with XRCC1 in nuclear DNA repair, and Isoform 1, which is crucial for mitochondrial DNA repair. These functions are vital for the preservation of cellular and mitochondrial DNA integrity, ensuring the proper functioning of cells.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Mitochondrial DNA depletion syndrome 20, MNGIE type, DNA ligase 3 presents a promising target for therapeutic intervention. This condition, marked by a spectrum of severe symptoms including neurological and muscular impairments, highlights the importance of DNA ligase 3 in mitochondrial health. Exploring DNA ligase 3's role further could lead to innovative treatments for mitochondrial diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.